News
-
Chemomab Receives European Orphan Drug Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
-
Chemomab Receives Regulatory Approval to Commence a Phase II Clinical Trial for CM-101 as Treatment of Primary Sclerosing Cholangitis
-
ChemomAb Announces Issuance of Composition of Matter Patent for CM-101 and Reinforces its IP Portfolio
-
ChemomAb announces the publication of a peer reviewed manuscript the theraputic effects of CM-101 targeting CCL24 in NASH and liver fibrosis: “A Blocking Monoclonal Antibody to CCL24 Allovates Liver Fibrosis and Inflammation in Experimental Models for Liver Damage”
-
ChemomAb Ltd., Announces Data from Phase 1 Study of CM-101 Subcutaneous Formulation Demonstrating Comparable Exposure to The Intravenous CM-101 Formulation
-
Chemomab announces a peer reviewed publication of preclinical proof of concept data supporting the pivotal role of CCL24 in systemic sclerosis and idiopathic pulmonary fibrosis. The paper “Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis” was published in May 2019 edition of “Annals of Rheumatoid Diseases” and supports the therapeutic potential of CM-101 for the treatment of patients with Systemic Sclerosis. Annals of Rheumatoid Diseases is a top line peer reviewed journal which publishes basic, clinical and translational novel scientific research, owned by the European League Against Rheumatism (EULAR) and BMJ.
-
Chemomab doses first subject in a phase 1 clinical trial of Subcutaneous injected CM-101 in healthy volunteers
-
Chemomab Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease
-
Chemomab appoints Bryan Jennings as Chief Financial Officer
-
Chemomab was granted an Orphan Drug Designation from the FDA for the treatment of Primary Sclerosing Cholangitis
-
Chemomab appoints Dr. Stephen Squinto as Chairman of the Board
-
Chemomab successfully completed Phase 1 in healthy volunteers, achieving its primary endpoint of safety, pharmacokinetics and pharmacodynamics
-
Chemomab completed a $10 million series B fund raising supported by Orbimed Israel, Peter Thiel, SBI Japan-Israel innovation Fund and Milestone venture.
-
Chemomab received OCS grant for the development of the CM101 program.
-
Chemomab initiated its first in man clinical trial to test the safety, pharmacokinetic and pharmacodynamic profile of its lead drug CM101 in healthy volunteers.
-
Chemomab assembles advisory board meeting with Scleroderma key opinion leaders to discuss the outline of its clinical trial in Washington.
-
Chemomab receives formal scientific advice from EMA for pre-clinical and clinical development of its lead first in class monoclonal antibody CM101.
-
Chemomab is granted approval for its patent: ” Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders ” in USA, Europe and Israel.
-
Chemomab has engaged CMC Biologics for a full manufacturing program to generate GMP material for clinical trials.
-
Chemomab received a second FDA approved orphan drug designation, for idiopathic pulmonary fibrosis treatment with CM101.
-
Chemomab was granted orphan drug designation by the FDA, to treat systemic sclerosis patients with CM101.
-
Chemomab received an orphan drug designation approval from the EMA for CM101 treatment in systemic sclerosis.
Events
-
Chemomab to participate at the 11th Annual Jefferies Virtual Global Healthcare Conference (November 17-19, 2020). Adi Mor, CEO, will be available to participate in a virtual one-on-one meetings with investors who are registered to attend the conference.
-
Chemomab to present at the Stifel 2020 Virtual Healthcare Conference (November 16-18, 2020). Adi Mor, CEO, will present Chemomab’s overview and will be available to participate in a virtual one-on-one meetings with investors who are registered to attend the conference.
-
Chemomab to present at the Inv€$tival Showcase Virtual Conference (November 11-16, 2020). Adi Mor, CEO, will present overview of Chemomab and will be available to participate in a virtual one-on-one meetings with investors who are registered to attend the conference.
-
Chemomab to participate Bio Europe Digital on October 26-29 for virtual one-on-one partnering meetings
-
Chemomab Announces Late-Breaking Presentation of CM-101 First Evidence of Anti-Fibrotic Activity in NAFLD Patients at the AASLD's The Liver Meeting Digital Experience™ 2020
-
Chemomab to present at the Bio Investor Forum Digital 2020. Adi Mor, CEO, will present at the Bio Investor Forum Digital (October 13-16) and will be available to participate in a virtual one-on-one meetings with investors who are registered to attend the conference.
-
Chemomab to present at the Citi’s 15th Annual BioPharma Virtual Conference. Adi Mor, CEO, will present at the Citi 2020 Virtual BioPharma Conference on Tuesday, September 8, 2020 at 08:20 am EST
-
Chemomab to present “CCL24 modulates fibrosis development in Primary Sclerosing Cholangitis. Correlation of human serum CCL24 levels with fibrosis markers and data from the MDR2-/- mice model” at the digital EASL International Liver Congress, 2020.
-
Chemomab to participate Bio-Digital for virtual one-on-one partnering meetings
-
Chemomab to present “CM-101 a novel CCL24 blocking monoclonal antibody attenuates HSC activation in vitro and reduces fibrosis in the TAA mice model” at AASLD International Liver Meeting in Boston, 2019
-
Chemomab to present “Attenuation of CCL24, using CM-101- a Novel monoclonal antibody, reduces cholangiocytes proliferation in experimental cholestasis models” at EASL International Liver Congress 2019.
-
Chemomab to Present “CM101, A novel CCL24 blocking antibody, suppresses hepatic injury and fibrosis in experimental models of NASH and liver fibrosis” at AASLD international Liver meeting in San Francisco 2018
-
Chemomab presents “A novel CCL24 blocking monoclonal antibody ameliorates liver injury in experimental models of cholestasis” at EASL International Liver Congress 2018.
-
Chemomab to present ” CM-101, a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model” at AASLD’s Liver Meeting® 2017.
-
Chemomab presents “Circulating levels of the chemokine CCL24 and its receptor in patients with non-alcoholic fatty liver disease” in the Israeli Liver convention.
-
Chemomab orally presented “CM-101, A Novel Monoclonal Antibody Blocking CCL24 Ameliorates Experimental Systemic Sclerosis (SSc) and Idiopathic Pulmonary Fibrosis (IPF) and a Novel Antibody Blocking CCL24/CCR3 Reduces Chemokines is of Immune Cells and The Transition of Fibroblasts to Myofibroblasts In Systemic Sclerosis (SSc)” in the Systemic Sclerosis World Congress.